Methods and compositions for inhibiting CD32B expressing cells

Patent metadata

Field	Value
Publication number	US-11434295-B2
Application number	US-201113294103-A
Country	US
Kind code	B2
Filing date	Nov 10, 2011
Priority date	May 30, 2007
Publication date	Sep 6, 2022
Grant date	Sep 6, 2022

Abstract

The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

First claim

We claim:

1. A method of inhibiting at least one B cell, comprising contacting the cell with an antibody that binds to CD19,
wherein the antibody comprises a light chain variable region comprising SEQ ID NO: 1 and a heavy chain variable region comprising SEQ ID NO: 2, and
an Fc region comprising an amino acid substitution S267E,
wherein the numbering is according to the EU index, as in Kabat.

2. The method according to claim 1 , wherein the antibody further comprises an amino acid substitution L328F in the Fc region of the antibody.

3. A method of inhibiting at least one B cell, comprising contacting the cell with an antibody comprising:
a) a light chain variable region comprising SEQ ID NO: 1;
b) a heavy chain variable region comprising SEQ ID NO: 2; and
c) a variant Fc human IgG1 domain comprising the amino acid substitution S267E, wherein the numbering is according to the EU index as in Kabat.

4. The method according to claim 3 , wherein the variant Fc human IgG1 domain of the antibody further comprises an amino acid substitution L328F.

5. The method according to claim 3 , wherein the variant Fc human IgG1 domain of the antibody consists of amino acid substitutions S267E and L328F in the Fc region.

Assignees

• Chu Seung Yup
• Desjarlais John R
• Karki Sher Bahadur
• Lazar Gregory Alan
• Moore Gregory L
• Vostiar Igor
• Xencor Inc

Inventors

• Chu Seung Yup
• Desjarlais John R
• Karki Sher Bahadur
• Lazar Gregory Alan
• Moore Gregory L
• Vostiar Igor

Classifications

• C07K16/00 Primary

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K2317/72

  Increased effector function due to an Fc-modification · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title